Alterations in the Cerebellar (Phospho)Proteome of a Cyclic Guanosine Monophosphate (cGMP)-dependent Protein Kinase Knockout Mouse

The cyclic nucleotide cyclic guanosine monophosphate (cGMP) plays an important role in learning and memory, but its signaling mechanisms in the mammalian brain are not fully understood. Using mass-spectrometry-based proteomics, we evaluated how the cerebellum adapts its (phospho)proteome in a knockout mouse model of cGMP-dependent protein kinase type I (cGKI). Our data reveal that a small subset of proteins in the cerebellum (∼3% of the quantified proteins) became substantially differentially expressed in the absence of cGKI. More changes were observed at the phosphoproteome level, with hundreds of sites being differentially phosphorylated between wild-type and knockout cerebellum. Most of these phosphorylated sites do not represent known cGKI substrates. An integrative computational network analysis of the data indicated that the differentially expressed proteins and proteins harboring differentially phosphorylated sites largely belong to a tight network in the Purkinje cells of the cerebellum involving important cGMP/cAMP signaling nodes (e.g. PDE5 and PKARIIβ) and Ca²⁺ signaling (e.g. SERCA3). In this way, removal of cGKI could be linked to impaired cerebellar long-term depression at Purkinje cell synapses. In addition, we were able to identify a set of novel putative (phospho)proteins to be considered in this network. Overall, our data improve our understanding of cerebellar cGKI signaling and suggest novel players in cGKI-regulated synaptic plasticity.Knockout (KO)¹ mouse models represent powerful methods for studying the physiological relevance of a protein. However, to elucidate the effects of KO-induced perturbations on the entire system, systems-wide molecular characterization is needed, as, for instance, provided by (phospho)proteomics. Recent technological and methodological advancements now allow the mapping of protein expression, at least in cell cultures, close to completion (1–3). More challenging, proteomics is also increasingly used to attempt systems-wide proteome characterizations in tissue. This has led to semi-quantitative (4–6) and quantitative (7) reasonably comprehensive proteome data on selected tissues, in both humans and animal models. More recently, proteomics has also been applied for the in-depth profiling of perturbations in the proteome occurring in KO models. For instance, de Graaf et al. (8) used an in-depth proteomic approach to identify the proteins changed by DNA-damage-induced premature aging, using a KO mouse model lacking the excision repair cross-complementing group 1 gene. Another recent study used a mouse model lacking apolipoprotein E in order to identify biomarker candidates for coronary artery disease (9).Adaptation and/or perturbations in the proteome caused by a KO can lead to changes in protein expression, but, at least equally likely, also to rewiring of signaling networks, through changes in post-translational modifications, such as protein phosphorylation. The application of (phospho)proteomics technology on KO or knock-in models is therefore also extremely relevant, albeit even more challenging. Hilger et al. (10) combined proteomics and phosphoproteomics on a cell line in which a phosphatase had been knocked out. To perform such experiments in a more (disease) relevant context, we should invest in functional, tissue-based phosphoproteomics approaches. A few examples of such approaches have very recently been reported. Lundby et al. (11) globally assessed phosphorylation events downstream of systemic adrenergic stimulation in mouse cardiac tissue. We recently reported on the use of a cardiac delimited CaMKII inhibited knock-in mouse to probe for substrates using a focused kinase-inhibition directed approach (12). Moreover, a mouse model lacking nitric oxide synthase (13), as a system of interest for Alzheimer disease, was recently studied via (phospho)proteomics.Here we explored how mature state-of-the-art (phospho)proteomics technology could be used to monitor the adaptation at the proteome level of the mouse cerebellum in a mouse line deficient for cGMP-dependent protein kinase type I (cGKI, also known as PKG-I), a kinase that plays an important role in synaptic plasticity, motor learning, and other brain functions (14). The cGMP-dependent protein kinases are serine/threonine kinases that act as key mediators of nitric oxide (NO) signaling, as well as of the natriuretic peptide pathway (15). In mammals, cGKs are encoded by two different genes: prkg1 coding for cGKI, and prkg2 coding for cGKII (16). The prkg1 gene encodes two cGKI isoforms, cGKIα and cGKIβ (17), which differ in their N-terminal leucine zipper and auto-inhibitory domains. cGKI regulates cardiovascular functions such as smooth muscle and cardiac contractility (16); in the nervous system it modulates synaptic plasticity in the hippocampus (18) and cerebellum (19).In the mammalian brain, more than 250 protein kinases are expressed, but only a few of these kinases are currently known to contribute to learning and memory. In particular, cGKIα is highly expressed in cerebellar Purkinje cells (PCs) (20, 21). Long-term depression (LTD) is an activity-dependent reduction in the efficacy of synaptic transmission and occurs at the PC synapses. Both a pharmacological approach using enzyme inhibitors (22) and a conditional PC-specific cGKI-KO (23) showed that cGKI plays a role in cerebellar LTD. Several proteins have been identified in past years as cGKI substrates in vitro or in cultured cells (15), but only a small portion of these have been confirmed as cGKI substrates in vivo. Therefore, the understanding of cGKI signaling and function depends strongly on the identification of novel in vivo substrates and signaling partners. In this perspective, the currently described approach allows us to discover potentially novel cGKI signaling routes and substrates directly in relevant cerebellar tissue. Our study revealed that cGKI-KO led to differential expression in the cerebellum of a specific group of proteins, of which many were closely connected to cGMP-cGKI signaling. More changes were observed at the phosphoproteome level, with the regulation of phosphorylation of a few hundred proteins. In particular, we hypothesize that some of the down-regulated phosphoproteins, but certainly not all, may be putative substrates of cGKI.